Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer

Isamu Okamoto, Eiji Moriyama, Shinji Fujii, Hiroto Kishi, Masanobu Nomura, Eisuke Goto, Chikage Kiyofuji, Fumiya Imamura, Takashi Mori, Mitsuhiro Matsumoto

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: More than 30% of cases of non-small cell lung cancer (NSCLC) arise in patients aged ≥ 70 years. The efficacy and safety of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced NSCLC were evaluated in a phase II trial. Methods: Twenty-five patients aged ≥ 70 years (median, 76; range, 70-83) with chemotherapy-naïve advanced NSCLC were enrolled between January 2001 and July 2003. Additional criteria included the presence of measurable lesions, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function. Patients received carboplatin at an area under the curve of 5 mg/ml/min and paclitaxel at 180 mg/m2 on the first day of consecutive 3 week periods. Results: The patients included four with stage IIIB, 19 with stage IV and two with recurrent disease. The median number of treatment cycles was three (range, 1-4). One complete response and six partial responses, yielding an objective response rate of 28%, were obtained. The median survival time was 12.3 months and the 1-year survival rate was 52%. Hematological toxicities of grade 3 or 4 included leukopenia (40%), neutropenia (68%) and anemia (4%). Non-hematological toxicities of grade 3 included arthralgia-myalgia (16%) and neuropathy (12%). The objective response rate for patients aged ≥ 75 years (n = 15) was 26%, and no evidence of excessive toxicity in these patients was apparent compared with those aged <75 years. Conclusion: The combination carboplatin-paclitaxel at these doses is a feasible treatment option with a favorable toxicity profile for fit elderly patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)188-194
Number of pages7
JournalJapanese journal of clinical oncology
Volume35
Issue number4
DOIs
Publication statusPublished - Apr 1 2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Okamoto, I., Moriyama, E., Fujii, S., Kishi, H., Nomura, M., Goto, E., Kiyofuji, C., Imamura, F., Mori, T., & Matsumoto, M. (2005). Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology, 35(4), 188-194. https://doi.org/10.1093/jjco/hyi059